Literature DB >> 17475917

Exon skipping through the creation of a putative exonic splicing silencer as a consequence of the cystic fibrosis mutation R553X.

Isabel Aznarez, Julian Zielenski, Johanna M Rommens, Benjamin J Blencowe, Lap-Chee Tsui.   

Abstract

Nonsense mutations that occur more than 50 bases upstream of terminal spliced junctions are generally thought to lead to degradation of the corresponding transcripts by the process of nonsense-mediated mRNA decay. It has also been proposed that some nonsense mutations may affect splicing by the process of nonsense-associated altered splicing (NAS), or by the disruption of a splicing regulatory element. In this study, the effect of the R553X mutation on the splicing of exon 11 of the cystic fibrosis transmembrane conductance regulator gene was investigated. Evidence that R553X causes exon 11 to skip through the creation of a putative exonic splicing silencer (ESS) was provided. The putative ESS appears to be active when located immediately upstream of a 5' splice site. These findings argue against the possibility that R553X-associated exon 11 skipping is caused by NAS. The study further suggests that aminoglycoside antibiotic treatment would not be effective for patients with the R553X mutation, owing to the skipping of exon 11, and further emphasises the need for detailed mechanistic characterisation of the consequences of nonsense disease mutations.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17475917      PMCID: PMC2597982          DOI: 10.1136/jmg.2006.045880

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  37 in total

Review 1.  Listening to silence and understanding nonsense: exonic mutations that affect splicing.

Authors:  Luca Cartegni; Shern L Chew; Adrian R Krainer
Journal:  Nat Rev Genet       Date:  2002-04       Impact factor: 53.242

Review 2.  NASty effects on fibrillin pre-mRNA splicing: another case of ESE does it, but proposals for translation-dependent splice site choice live on.

Authors:  Lynne E Maquat
Journal:  Genes Dev       Date:  2002-07-15       Impact factor: 11.361

3.  Correction of disease-associated exon skipping by synthetic exon-specific activators.

Authors:  Luca Cartegni; Adrian R Krainer
Journal:  Nat Struct Biol       Date:  2003-02

4.  General and specific functions of exonic splicing silencers in splicing control.

Authors:  Zefeng Wang; Xinshu Xiao; Eric Van Nostrand; Christopher B Burge
Journal:  Mol Cell       Date:  2006-06-22       Impact factor: 17.970

5.  Genetic modifiers of lung disease in cystic fibrosis.

Authors:  Mitchell L Drumm; Michael W Konstan; Mark D Schluchter; Allison Handler; Rhonda Pace; Fei Zou; Maimoona Zariwala; David Fargo; Airong Xu; John M Dunn; Rebecca J Darrah; Ruslan Dorfman; Andrew J Sandford; Mary Corey; Julian Zielenski; Peter Durie; Katrina Goddard; James R Yankaskas; Fred A Wright; Michael R Knowles
Journal:  N Engl J Med       Date:  2005-10-06       Impact factor: 91.245

6.  Normal function of the cystic fibrosis conductance regulator protein can be associated with homozygous (Delta)F508 mutation.

Authors:  Isabelle Sermet-Gaudelus; Benoit Vallée; Ilse Urbin; Tania Torossi; Rémi Marianovski; Anne Fajac; Marie-Noëlle Feuillet; Jean-Louis Bresson; Gérard Lenoir; Jean François Bernaudin; Aleksander Edelman
Journal:  Pediatr Res       Date:  2002-11       Impact factor: 3.756

7.  Alpha 1-antitrypsin deficiency alleles in cystic fibrosis lung disease.

Authors:  Despina D Frangolias; Jian Ruan; Pearce J Wilcox; A George F Davidson; Lawrence T K Wong; Yves Berthiaume; Rosamund Hennessey; Andreas Freitag; Linda Pedder; Mary Corey; Neil Sweezey; Julian Zielenski; Elizabeth Tullis; Andrew J Sandford
Journal:  Am J Respir Cell Mol Biol       Date:  2003-04-14       Impact factor: 6.914

8.  Molecular consequences of cystic fibrosis transmembrane regulator (CFTR) gene mutations in the exocrine pancreas.

Authors:  N Ahmed; M Corey; G Forstner; J Zielenski; L-C Tsui; L Ellis; E Tullis; P Durie
Journal:  Gut       Date:  2003-08       Impact factor: 23.059

9.  Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy.

Authors:  L Brichta; Y Hofmann; E Hahnen; F A Siebzehnrubl; H Raschke; I Blumcke; I Y Eyupoglu; B Wirth
Journal:  Hum Mol Genet       Date:  2003-07-29       Impact factor: 6.150

10.  Alternatively spliced TCR mRNA induced by disruption of reading frame.

Authors:  Jun Wang; John I Hamilton; Mark S Carter; Shulin Li; Miles F Wilkinson
Journal:  Science       Date:  2002-07-05       Impact factor: 47.728

View more
  5 in total

1.  CFTR transcription defects in pancreatic sufficient cystic fibrosis patients with only one mutation in the coding region of CFTR.

Authors:  Molly B Sheridan; Timothy W Hefferon; Nulang Wang; Christian Merlo; Carlos Milla; Drucy Borowitz; Eric D Green; Peter J Mogayzel; Garry R Cutting
Journal:  J Med Genet       Date:  2010-11-20       Impact factor: 6.318

2.  Evidence in disease and non-disease contexts that nonsense mutations cause altered splicing via motif disruption.

Authors:  Liam Abrahams; Rosina Savisaar; Christine Mordstein; Bethan Young; Grzegorz Kudla; Laurence D Hurst
Journal:  Nucleic Acids Res       Date:  2021-09-27       Impact factor: 16.971

3.  Nonsense-associated altered splicing of MAP3K1 in two siblings with 46,XY disorders of sex development.

Authors:  Maki Igarashi; Yohei Masunaga; Yuichi Hasegawa; Kenichi Kinjo; Mami Miyado; Hirotomo Saitsu; Yuko Kato-Fukui; Reiko Horikawa; Yomiko Okubo; Tsutomu Ogata; Maki Fukami
Journal:  Sci Rep       Date:  2020-10-15       Impact factor: 4.379

4.  A novel nonsense variant in ARID1B causing simultaneous RNA decay and exon skipping is associated with Coffin-Siris syndrome.

Authors:  Viktoriia Sofronova; Yu Fukushima; Mitsuo Masuno; Mami Naka; Miho Nagata; Yasuki Ishihara; Yohei Miyashita; Yoshihiro Asano; Takahito Moriwaki; Rina Iwata; Seigo Terawaki; Yasuko Yamanouchi; Takanobu Otomo
Journal:  Hum Genome Var       Date:  2022-07-25

Review 5.  Splicing mutations in the CFTR gene as therapeutic targets.

Authors:  Karine Deletang; Magali Taulan-Cadars
Journal:  Gene Ther       Date:  2022-06-02       Impact factor: 4.184

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.